Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results Read more about Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results
Amgen Announces Termination of Poison Pill Effective July 31, 2006 Read more about Amgen Announces Termination of Poison Pill Effective July 31, 2006
ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption Read more about ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption
Amgen Announces Webcast of Second Quarter Financial Results Read more about Amgen Announces Webcast of Second Quarter Financial Results
Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology Read more about Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology
Final Results of Phase 2 Clinical Trial Program Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Decrease Risk of Hospitalization and All-Cause Mortality in Heart Failure Patients with Anemia, Based on a Prespecified Pooled Analysis Read more about Final Results of Phase 2 Clinical Trial Program Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Decrease Risk of Hospitalization and All-Cause Mortality in Heart Failure Patients with Anemia, Based on a Prespecified Pooled Analysis
FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer Read more about FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer
Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases Read more about Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases
Interim Data Suggest Potential Benefits of Aranesp(R) Dosed Every Three Weeks with Intravenous Iron for Chemotherapy-Induced Anemia; 94 Percent of Patients Achieved Target Hemoglobin Level Read more about Interim Data Suggest Potential Benefits of Aranesp(R) Dosed Every Three Weeks with Intravenous Iron for Chemotherapy-Induced Anemia; 94 Percent of Patients Achieved Target Hemoglobin Level
New Interim Phase 2 Data Suggest the Antitumor Activity of Panitumumab in Metastatic Colorectal Cancer Read more about New Interim Phase 2 Data Suggest the Antitumor Activity of Panitumumab in Metastatic Colorectal Cancer
